Barnes Jewish Hospital, Washington University St. Louis, St. Louis, MO, USA.
University of Kentucky, Lexington, KY, USA.
Neurocrit Care. 2017 Oct;27(2):242-248. doi: 10.1007/s12028-016-0343-x.
Little data exist regarding the practice of sodium management in acute neurologically injured patients. This study describes the practice variations, thresholds for treatment, and effectiveness of treatment in this population.
This retrospective, multicenter, observational study identified 400 ICU patients, from 17 centers, admitted for ≥48 h with subarachnoid hemorrhage (SAH), traumatic brain injury (TBI), intraparenchymal hemorrhage, or intracranial tumors between January 1, 2011 and July 31, 2012. Data collection included demographics, APACHE II, Glascow Coma Score (GCS), serum sodium (Na+), fluid rate and tonicity, use of sodium-altering therapies, intensive care unit (ICU) and hospital length of stay, and modified Rankin score upon discharge. Data were collected for the first 21 days of ICU admission or ICU discharge, whichever came first. Sodium trigger for treatment defined as the Na+ value prior to treatment with response defined as an increase of ≥4 mEq/L at 24 h.
Sodium-altering therapy was initiated in 34 % (137/400) of patients with 23 % (32/137) having Na >135 mEq/L at time of treatment initiation. The most common indications for treatment were declining serum Na (68/116, 59 %) and cerebral edema with mental status changes (21/116, 18 %). Median Na treatment trigger was 133 mEq/L (IQR 129-139) with no difference between diagnoses. Incidence and treatment of hyponatremia was more common in SAH and TBI [SAH (49/106, 46 %), TBI (39/97, 40 %), ICH (27/102, 26 %), tumor (22/95, 23 %); p = 0.001]. The most common initial treatment was hypertonic saline (85/137, 62 %), followed by oral sodium chloride tablets (42/137, 31 %) and fluid restriction (15/137, 11 %). Among treated patients, 60 % had a response at 24 h. Treated patients had lower admission GCS (12 vs. 14, p = 0.02) and higher APACHE II scores (12 vs. 10, p = 0.001). There was no statistically significant difference in outcome when comparing treated and untreated patients.
Sodium-altering therapy is commonly employed among neurologically injured patients. Hypertonic saline infusions were used first line in more than half of treated patients with the majority having a positive response at 24 h. Further studies are needed to evaluate the impact of various treatments on patient outcomes.
关于急性神经损伤患者的钠管理实践,相关数据较少。本研究描述了该人群中的治疗实践差异、治疗阈值和治疗效果。
这是一项回顾性、多中心、观察性研究,纳入了 2011 年 1 月 1 日至 2012 年 7 月 31 日期间,17 个中心的 400 名 ICU 患者,这些患者的亚急性蛛网膜下腔出血(SAH)、创伤性脑损伤(TBI)、脑实质出血或颅内肿瘤的住院时间超过 48 小时。数据收集包括人口统计学、APACHE II 评分、格拉斯哥昏迷评分(GCS)、血清钠(Na+)、液体速度和渗透压、使用改变钠的治疗方法、入住 ICU 时间和住院时间,以及出院时的改良 Rankin 评分。数据收集了 ICU 入院后的前 21 天或 ICU 出院,以先发生的为准。治疗的钠触发定义为治疗前的 Na+值,反应定义为 24 小时内增加≥4 mEq/L。
34%(137/400)的患者开始接受改变钠的治疗,其中 23%(32/137)在治疗开始时的血清 Na+值>135 mEq/L。治疗的最常见指征是血清 Na 下降(68/116,59%)和伴有精神状态改变的脑水肿(21/116,18%)。中位数的 Na 治疗触发值为 133 mEq/L(IQR 129-139),不同诊断之间无差异。SAH 和 TBI 患者的低钠血症发生率和治疗率更高[SAH(49/106,46%),TBI(39/97,40%),ICH(27/102,26%),肿瘤(22/95,23%);p=0.001]。最常见的初始治疗是高渗盐水(85/137,62%),其次是口服氯化钠片(42/137,31%)和液体限制(15/137,11%)。在接受治疗的患者中,60%在 24 小时内有反应。治疗组患者入院时 GCS 评分较低(12 分比 14 分,p=0.02),APACHE II 评分较高(12 分比 10 分,p=0.001)。在比较治疗组和未治疗组患者时,没有统计学意义上的差异。
改变钠的治疗在神经损伤患者中普遍使用。超过一半的治疗患者首先使用高渗盐水,其中大多数在 24 小时内有阳性反应。需要进一步研究评估不同治疗方法对患者预后的影响。